Ramzi Benamar serves as Chief Financial Officer and is a member of DBV’s Executive Committee, responsible for leading financial strategy, overseeing DBV’s finance team, and managing the financing wellbeing of the company.
Mr. Benamar brings more than 20 years of industry experience with significant financial leadership capabilities, a focus on capital deployment strategies, and a rich background in both R&D and commercial biotechnology companies. Prior to joining DBV in January 2020, Mr. Benamar served as Vice President and Head of Financial Planning and Analysis at Spark Therapeutics where he was responsible for financial management, financial analysis & planning, business partnering and performance reporting. He contributed to the transition of Spark Therapeutics from a late-stage to a commercial stage company, including being part of the team that launched the first gene therapy in the United States. Spark Therapeutics was acquired by Roche Holdings AG in December 2019 for $4.3B. Before joining Spark Therapeutics, Mr. Benamar held various Finance and Operations positions of increasing responsibilities at Shire Plc, Johnson & Johnson, and Merck and Co.
Originally from Lyon, France, Mr. Benamar speaks fluent French and English. Mr. Benamar earned both his M.B.A and B.B.A in Marketing and Finance from Temple University, and his Master of Healthcare and Pharmaceutical Business Administration from University of the Sciences in Philadelphia.